

**Synthesis, Characterization and Biological Evaluation
of Hybrid Copper(II) Hybrid containing azole drugs and planar
ligands: As prospective antileishmanial agents**

Supplementary Materials




Figure S1: Absorption spectra of compounds 1 in the range of 250-800 nm recorded in DMSO in the interval of t = 0h to 24h.




Figure S2: Absorption spectra of compound 2 in the range of 250-800 nm recorded in DMSO in the interval of $t = 0\text{h}$ to 24h.




Figure S3: Absorption spectra of compound 3 in the range of 250-800 nm recorded in DMSO in the interval of $t = 0\text{h}$ to 24h.




Figure S4: Absorption spectra of compound 4 in the range of 250-800 nm recorded in DMSO in the interval of $t = 0\text{h}$ to 24h.




Figure S5: Absorption spectra of compound 5 in the range of 250-800 nm recorded in DMSO in the interval of $t = 0\text{h}$ to 24h.




Figure S6: Absorption spectra of compound 6 in the range of 250-800 nm recorded in DMSO in the interval of $t = 0\text{h}$ to 24h.




Figure S7. Experimental and simulated X-band CW EPR spectra obtained on a 0.5 mM frozen solution of **2** in DMF/EtOH 5:1.

Table S1. Best-fit parameters obtained from the simulation of X-band CW EPR measurement on a 0.5 mM frozen solution of **2** in DMF/EtOH 5:1.

| | g_x | g_y | g_z | A_x (MHz) | A_y (MHz) | A_z (MHz) | $^N A_{iso}$ (MHz) |
|-------------------------------------|----------|----------|----------|----------------|----------------|----------------|-----------------------|
| Cu | 2.065(2) | 2.065(2) | 2.267(1) | 40(2) | 40(2) | 538(2) | |
| N₁, N₂ | | | | | | | 41(1) |
| N₃, N₄ | | | | | | | 39(1) |